Ultime notizie per Evoke Pharma (NASDAQ:EVOK) Azioni

Evoke Pharma

Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.

Evoke Pharma Inc

EVOKAI CREATIVE LABS INC by EVOKAI CREATIVE LABS INC.

EvokAI Creative Labs Inc

888 HOLDINGS PLC ORD by 888 Holdings plc.

Evoke PLC

Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) reported quarterly losses of $(0.94) per share which missed the analyst consensus estimate of $(0.38) by 147.37 percent. The company reported quarterly sales of $2.70 million which missed the analyst consensus estimate of $3.36 million by 19.59 percent. This is a 72.74 percent increase over sales of $1.56 million the same period last year.

Earnings

Earnings Misses

News

EVOK

Evoke Pharma Q3 2024 GAAP EPS $(0.94) Misses $(0.38) Estimate, Sales $2.70M Miss $3.36M Estimate

Shares of V.F. Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) rose sharply in today's pre-market trading after the company reported better-than-expected<a href="https://www.benzinga.com/news/earnings/24/10/41587808/vf-corp-q2-earnings-revenue-beat-eps-beat-cost-reductions-on-track-guidance-and-more"> second-quarter financial results.</a>
VF Corp, the parent company of Vans and The North Face, reported second-quarter revenue of $2.8 billion, beating the consensus estimate of $2.7 billion, according to Benzinga Pro. The company reported second-quarter earnings of 60 cents per share, beating analyst estimates of 37 cents per share.
V.F. Corporation shares jumped 21.4% to $20.70 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) gained 68.2% to $2.22 in pre-market trading after the company announced it finalized agreements with all six of the planned site enrollment locations to administer the Phase 2 clinical trial of Ropidoxuridine.</li>
<li>Lixte Biotechnology Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) rose 67.6% to $2.23 in pre-market trading after falling 18% on Monday.</li>
<li>American Rebel Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) shares surged 30% to $3.51 in pre-market trading.</li>
<li>Immuron Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRN#NASDAQ">IMRN</a>) shares rose 29% to $2.49 in pre-market trading.</li>
<li>Lightbridge Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTBR#NASDAQ">LTBR</a>) climbed 15.4% to $10.48 in pre-market trading after jumping around 24% on Monday.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) gained 14.8% to $1.47 in pre-market trading. Quantum Computing will host a conference call and webcast on Wednesday, Nov. 6, to review the Company&#8217;s operational progress for the third quarter.</li>
<li>F5, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) gained 11.1% to $242.50 in pre-market trading after the company reported better-than-expected fourth-quarter financial results and approved an additional $1 billion buyback program.</li>
<li>Veea Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEA#NASDAQ">VEEA</a>) shares gained 10.7% to $4.32 in pre-market trading. Veea, O.N.E. Amazon, and AECOM partnered on &#8216;Internet of Forests&#8217; to digitally safeguard rainforests and empower Colombian communities.</li>
<li>Griid Infrastructure Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRDI#NASDAQ">GRDI</a>) shares rose 9.4% to $1.01 in pre-market trading after dipping 16% on Monday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Hanryu Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRYU#NASDAQ">HRYU</a>) shares dipped 40.4% to $0.3031 in pre-market trading after jumping 125% on Monday.</li>
<li>TransMedics Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) shares fell 25.8% to $93.69 in pre-market trading following downbeat quarterly results.</li>
<li>CVR Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVI#NYSE">CVI</a>) shares fell 25.8% to $17.68 in pre-market trading after the company reported weak quarterly results and said it will not pay cash dividend for the third quarter.</li>
<li>Digital Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) fell 21.3% to $0.1217 in today's pre-market trading after the company announced the pricing of $3 million public offering of common stock and/or pre-funded warrants.</li>
<li>Cardio Diagnostics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) fell 16.6% to $0.26 in pre-market trading after jumping 40% on Monday.</li>
<li>Evoke Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) fell 16% to $5.95 in pre-market trading. Evoke Pharma shares jumped 38% on Monday after the company announced the presentation of GLP-1 data for users with diabetic gastoparesis using GIMOTI and showed statistically significant improvements.</li>
<li>Harmonic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) shares declined 15.8% to $12.48 in pre-market trading after reporting third-quarter results.</li>
<li>Iveda Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVDA#NASDAQ">IVDA</a>) declined 15.6% to $1.40 in pre-market trading.</li>
<li>Amkor Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) shares fell 11% to $26.27 after the company reported mixed third-quarter financial results.</li>
<li>Daqo New Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DQ#NYSE">DQ</a>) fell 10.1% to $26.20 in pre-market trading after gaining 14% on Monday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41592226/dow-surges-over-250-points-ahead-of-alphabet-pfizer-earnings-investor-sentiment-improves-fear-index">Dow Surges Over 250 Points Ahead Of Alphabet, Pfizer Earnings: Investor Sentiment Improves, Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

AMKR

AREB

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

DBGI

FFIV

GRDI

HLIT

HRYU

IMRN

IVDA

LIXT

LTBR

QUBT

SHPH

TMDX

VEEA

Why VF Corp Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock moved upwards by 51.6% to $2.0 during Monday's after-market session. The company's market cap stands at $5.8 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares increased by 12.99% to $2.26. The company's market cap stands at $25.9 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) shares moved upwards by 12.01% to $4.01. The company's market cap stands at $33.2 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock moved upwards by 7.5% to $1.0. The company's market cap stands at $16.2 million. </li>
<li>NextCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTC#NASDAQ">NXTC</a>) stock moved upwards by 6.61% to $1.45. The market value of their outstanding shares is at $40.5 million. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) stock increased by 5.92% to $0.44. The company's market cap stands at $4.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) shares fell 28.6% to $90.2 during Monday's after-market session. The market value of their outstanding shares is at $3.0 billion. As per the press release, Q3 earnings came out today. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) shares fell 21.62% to $0.24. The market value of their outstanding shares is at $7.4 million. </li>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) stock decreased by 18.06% to $14.61. The market value of their outstanding shares is at $51.4 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares fell 8.62% to $6.47. The market value of their outstanding shares is at $4.7 million. </li>
<li>QT Imaging Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTI#NASDAQ">QTI</a>) shares fell 6.2% to $0.79. The market value of their outstanding shares is at $16.8 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) stock declined by 5.84% to $2.58. The company's market cap stands at $6.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BSGM

GNPX

MNPR

NXTC

ONCO

SYRA

12 Health Care Stocks Moving In Monday's After-Market Session

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 300 points on Monday.
The Dow traded up 0.77% to 42,440.12 while the NASDAQ rose 0.46% to 18,603.67. The S&amp;P 500 also rose, gaining, 0.43% to 5,832.99.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/10/41573022/how-to-earn-500-a-month-from-ford-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Ford Stock Ahead Of Q3 Earnings</a>
Leading and Lagging Sectors Financials shares rose by 1.2% on Monday.
In trading on Monday, energy shares fell by 0.7%.
Top Headline
Koninklijke Philips NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) reported third-quarter adjusted EPS of 0.32 euros (or $0.35), missing the consensus of 0.35 euros. The Dutch conglomerate reported sales of 4.38 billion euros ($4.74 billion), down 2% year over year and missing the consensus of 4.54 billion euros.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Healthcare Triangle, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares shot up 106% to $1.19 &nbsp;after the company disclosed in a filing that it acquired the business, assets, and operations relating to cloud and technology domain of Securekloud Technologies.</li>
<li>Shares of Autonomix Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) got a boost, surging 70% to $13.08 &nbsp;after the company reported preliminary results from its clinical trial of RF Ablation technology where 100% of its responder group was able to eliminate opioid use and reduce pain scores.</li>
<li>Evoke Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares were also up, gaining 52% to $7.78 after the company announced the presentation of GLP-1 data for users with diabetic gastoparesis using GIMOTI and showed statistically significant improvements.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Koninklijke Philips N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) shares dropped 16% to $26.52 after the company reported third-quarter EPS and sales below estimates and revised its 2024 outlook due to weak demand in China.</li>
<li>Shares of Borr Drilling Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BORR#NYSE">BORR</a>) were down 7% to $4.38. The stock may be moving on continued weakness following Friday&#8217;s reported preliminary third-quarter financial results.</li>
<li>CEMEX, S.A.B. de C.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CX#NYSE">CX</a>) was down, falling 9% to $5.46 following weak quarterly results.</li>
</ul>
Commodities In commodity news, oil traded down 6% to $67.49 while gold traded down 0.1% at $2,754.40.
Silver traded up 0.2% to $33.850 on Monday, while copper fell 0.1% to $4.3655.
Euro zone
European shares closed higher today. The eurozone's STOXX 600 gained 0.41%, Germany's DAX rose 0.35% and France's CAC 40 rose 0.79%. Spain's IBEX 35 Index rose 0.77%, while London's FTSE 100 rose 0.45%.
Retail sales in Spain rose by 4.1% year-over-year in September, while retail sales volumes in the UK fell by 6% in October following a 4% increase in September.
Asia Pacific Markets
Asian markets closed higher on Monday, with Japan's Nikkei 225 gaining 1.82%, Hong Kong's Hang Seng Index gaining 0.05%, China's Shanghai Composite Index gaining 0.68% and India's BSE Sensex surging 0.76%.
Hong Kong&#8217;s trade deficit shrank to $53.2 billion in September from $64.6 billion in the year-ago month.
Economics
The Federal Reserve Bank of Dallas&#8217; general business activity index for manufacturing in Texas rose to -3 in October compared to a reading of -9 in the earlier month.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41570746/top-3-real-estate-stocks-that-may-surge-in-q4">Top 3 Real Estate Stocks That May Surge In Q4</a></li>
</ul>

Equities

Eurozone

Commodities

AMIX

BORR

HCTI

S&P 500 Moves Higher; Philips Shares Plunge After Q3 Earnings

<h3>Gainers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock rose 124.5% to $1.3 during Monday's regular session. The market value of their outstanding shares is at $7.3 million. </li>
<li>Monte Rosa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLUE#NASDAQ">GLUE</a>) shares increased by 117.99% to $10.66. The market value of their outstanding shares is at $654.2 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares rose 69.81% to $9.0. The company's market cap stands at $6.6 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares moved upwards by 44.51% to $6.72. The company's market cap stands at $87.4 million. </li>
<li>EyePoint Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>) shares moved upwards by 36.31% to $12.95. The market value of their outstanding shares is at $693.0 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares increased by 30.8% to $2.59. The company's market cap stands at $6.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) shares fell 18.3% to $4.91 during Monday's regular session. The company's market cap stands at $25.5 million. </li>
<li>Koninklijke Philips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) stock decreased by 15.92% to $26.63. The market value of their outstanding shares is at $24.8 billion. The company's, Q3 earnings came out today. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock declined by 14.11% to $2.62. The company's market cap stands at $447.0 million. </li>
<li>Iterum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>) shares decreased by 13.83% to $1.62. The market value of their outstanding shares is at $36.7 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock fell 12.85% to $0.73. The company's market cap stands at $1.4 million. </li>
<li>Aptorum Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) shares declined by 12.73% to $1.44. The market value of their outstanding shares is at $7.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CYCC

EYPT

GLUE

ITRM

SONN

TVGN

12 Health Care Stocks Moving In Monday's Intraday Session

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 200 points on Monday.
The Dow traded up 0.52% to 42,333.84 while the NASDAQ rose 0.43% to 18,598.02. The S&amp;P 500 also rose, gaining, 0.31% to 5,826.12.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/10/41573022/how-to-earn-500-a-month-from-ford-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Ford Stock Ahead Of Q3 Earnings</a>
Leading and Lagging Sectors Utilities shares rose by 1.1% on Monday.
In trading on Monday, energy shares fell by 1%.
Top Headline
ON Semiconductor Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) posted better-than-expected earnings for the third quarter on Monday.
The company posted a revenue decline of 19.2% year-on-year to $1.76 billion, beating the analyst consensus estimate of $1.75 billion. The adjusted EPS of 99 cents beat the analyst consensus estimate of 97 cents.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Healthcare Triangle, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares shot up 159% to $1.50 after the company disclosed in a filing that it acquired the business, assets, and operations relating to cloud and technology domain of Securekloud Technologies.</li>
<li>Shares of Autonomix Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) got a boost, surging 78% to $13.73 after the company reported preliminary results from its clinical trial of RF Ablation technology where 100% of its responder group was able to eliminate opioid use and reduce pain scores.</li>
<li>Evoke Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares were also up, gaining 82% to $9.34 after the company announced the presentation of GLP-1 data for users with diabetic gastoparesis using GIMOTI and showed statistically significant improvements.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Koninklijke Philips N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) shares dropped 17% to $26.16 after the company reported third-quarter EPS and sales below estimates and revised its 2024 outlook due to weak demand in China.</li>
<li>Shares of Borr Drilling Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BORR#NYSE">BORR</a>) were down 11% to $4.1987. The stock may be moving on continued weakness following Friday&#8217;s reported preliminary third-quarter financial results.</li>
<li>CEMEX, S.A.B. de C.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CX#NYSE">CX</a>) was down, falling 10% to $5.36 following weak quarterly results.</li>
</ul>
Commodities In commodity news, oil traded down 5.4% to $67.88 while gold traded up 0.1% at $2,755.50.
Silver traded up 0.3% to $33.890 on Monday, while copper fell 0.1% to $4.3660.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.10%, Germany's DAX fell 0.02% and France's CAC 40 rose 0.39%. Spain's IBEX 35 Index rose 0.37%, while London's FTSE 100 rose 0.16%.
Retail sales in Spain rose by 4.1% year-over-year in September, while retail sales volumes in the UK fell by 6% in October following a 4% increase in September.
Asia Pacific Markets
Asian markets closed higher on Monday, with Japan's Nikkei 225 gaining 1.82%, Hong Kong's Hang Seng Index gaining 0.05%, China's Shanghai Composite Index gaining 0.68% and India's BSE Sensex surging 0.76%.
Hong Kong&#8217;s trade deficit shrank to $53.2 billion in September from $64.6 billion in the year-ago month.
Economics
The Federal Reserve Bank of Dallas&#8217; general business activity index for manufacturing in Texas rose to -3 in October compared to a reading of -9 in the earlier month. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41570746/top-3-real-estate-stocks-that-may-surge-in-q4">Top 3 Real Estate Stocks That May Surge In Q4</a></li>
</ul>

Intraday Update

Crude Oil Tumbles Over 5%; Autonomix Medical Shares Spike Higher

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday.
Following the market opening Monday, the Dow traded up 0.81% to 42,454.94 while the NASDAQ rose 0.53% to 18,616.62. The S&amp;P 500 also rose, gaining, 0.45% to 5,834.35.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/10/41573022/how-to-earn-500-a-month-from-ford-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Ford Stock Ahead Of Q3 Earnings</a>
Leading and Lagging Sectors Real estate shares rose by 1% on Monday.
In trading on Thursday, energy shares fell by 1.6%.
Top Headline
ON Semiconductor Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) posted better-than-expected earnings for the third quarter on Monday.
The company posted a revenue decline of 19.2% year-on-year to $1.76 billion, beating the analyst consensus estimate of $1.75 billion. The adjusted EPS of 99 cents beat the analyst consensus estimate of 97 cents.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Healthcare Triangle, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares shot up 157% to $1.49 after the company disclosed in a filing that it acquired the business, assets, and operations relating to cloud and technology domain of Securekloud Technologies.</li>
<li>Shares of Autonomix Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) got a boost, surging 126% to $17.48 after the company reported preliminary results from its clinical trial of RF Ablation technology where 100% of its responder group was able to eliminate opioid use and reduce pain scores.</li>
<li>Evoke Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares were also up, gaining 114% to $10.99 after the company announced the presentation of GLP-1 data for users with diabetic gastoparesis using GIMOTI and showed statistically significant improvements.</li>
</ul>
Equities Trading DOWN
<ul>
<li>SMX (Security Matters) Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) shares dropped 66% to $0.4686.</li>
<li>Shares of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) were down 19% to $4.84. Sonnet BioTherapeutics recently announced it regained compliance with Nasdaq.</li>
<li>Upexi, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPXI#NASDAQ">UPXI</a>) was down, falling 23% to $6.26. Upexi shares jumped 170% on Friday after the company said it is currently reviewing trading activity to determine if recent activity involved possible stock manipulation.</li>
</ul>
Commodities In commodity news, oil traded down 5.8% to $67.63 while gold traded down 0.1% at $2,753.30.
Silver traded up 0.4% to $33.915 on Monday, while copper fell 0.3% to $4.3585.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.2%, Germany's DAX gained 0.1% and France's CAC 40 rose 0.5%. Spain's IBEX 35 Index rose 0.4%, while London's FTSE 100 rose 0.1%.
Retail sales in Spain rose by 4.1% year-over-year in September, while retail sales volumes in the UK fell by 6% in October following a 4% increase in September.
Asia Pacific Markets
Asian markets closed higher on Monday, with Japan's Nikkei 225 gaining 1.82%, Hong Kong's Hang Seng Index gaining 0.05%, China's Shanghai Composite Index gaining 0.68% and India's BSE Sensex surging 0.76%.
Hong Kong&#8217;s trade deficit shrank to $53.2 billion in September from $64.6 billion in the year-ago month.
Economics
The Dallas Fed Manufacturing Index will be released today.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41570746/top-3-real-estate-stocks-that-may-surge-in-q4">Top 3 Real Estate Stocks That May Surge In Q4</a></li>
</ul>

Price Target

Analyst Ratings

UPXI

Dow Jumps Over 300 Points; ON Semiconductor Earnings Top Views

Evoke Pharma Shares Resume Trade

Evoke Pharma Shares Halted To The Upside; Stock Now Up 107.36%

Evoke Pharma Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares are trading higher Monday after the company presented GLP-1 data for users with diabetic gastoparesis using GIMOTI showing <a href="https://www.benzinga.com/pressreleases/24/10/g41569704/evoke-pharma-eversana-announce-statistically-significant-improvement-in-patient-outcomes-for-glp-1">statistically significant improvements</a>.
What Happened: Evoke Pharma announced Monday morning the results from a real-world retrospective study evaluating the impact of GIMOTI (metoclopramide nasal spray) in patients with diabetic gastroparesis (DGP) who were concurrently using GLP-1 receptor agonists.
The study compared healthcare resource utilization (HRU) between patients using GIMOTI nasal metoclopramide (NMCP) and those on oral metoclopramide (OMCP), specifically focusing on individuals with a prior GLP-1 prescription.&nbsp;
Evoke said patients with prior GLP-1 history had reduced HRU after taking NMCP. For patients taking GLP-1, those that took NMCP had fewer healthcare visits compared to those taking OMCP. The company also found that NMCP can be used to effectively treat patients with gastroparesis taking GLP-1 treatment and avoid costly healthcare visits.
&#8220;This data is particularly encouraging given the rising number of patients using GLP-1 agonists for diabetes, many of whom also suffer from gastroparesis,&#8221; said Matt D&#8217;Onofrio, CEO of Evoke Pharma. 
&#8220;Our goal is to provide data regarding Gimoti as supportive care for diabetic gastroparesis for those also on GLP-1 agonists. This study, combined with the earlier real-world data presented at key conferences, reinforces GIMOTI&#8217;s potential to improve outcomes for patients and reduce the overall financial burden on the healthcare system.&#8221;
See Also: <a href="https://www.benzinga.com/markets/equities/24/10/41570418/boeing-eyes-15b-fundraise-as-it-struggles-due-to-strikes-and-mounting-losses-report">Boeing Eyes $15B Fundraise As It Struggles Due To Strikes And Mounting Losses: Report</a>
Evoke said these results build on data presented at&nbsp;Digestive Disease Week 2024&nbsp;and&nbsp;ACG 2023&nbsp;that demonstrated that patients treated with GIMOTI showed&nbsp;fewer hospitalizations, emergency department visits and physician office visits&nbsp;compared to those using oral metoclopramide.
Evoke Pharma&#8217;s average session volume over the past 100 days is about 72,000, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. Monday&#8217;s trading volume was around 8.16 million at the time of writing. 
Evoke is considered a low-float stock with approximately 727,000 shares available for public trading, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.&nbsp; The company also had a market cap of less than $4 million as of Friday&#8217;s close. Low-float, micro-cap stocks can be extremely volatile, which may help explain some of Monday&#8217;s surge. 
EVOK Price Action: <a href="https://www.benzinga.com/quote/EVOK">Evoke Pharma shares</a> were up 128.1% at $12.09 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Evoke Pharma Stock Is Soaring Monday: What's Going On?

WIIM

Evoke Pharma shares are trading higher after the company announced the presentation of GLP-1 data for users with diabetic gastoparesis using GIMOTI and showed statistically significant improvements.

<h3>Gainers</h3>
<ul>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) stock increased by 128.3% to $12.1 during Monday's pre-market session. The market value of their outstanding shares is at $8.8 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock moved upwards by 93.43% to $1.12. The market value of their outstanding shares is at $6.3 million. </li>
<li>Monte Rosa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLUE#NASDAQ">GLUE</a>) shares rose 30.47% to $6.38. The market value of their outstanding shares is at $391.5 million. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) stock increased by 21.06% to $5.69. The company's market cap stands at $592.7 million. </li>
<li>PROCEPT BioRobotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>) stock moved upwards by 14.87% to $79.0. The company's market cap stands at $4.1 billion. The company's, Q3 earnings came out today. </li>
<li>Avalo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) stock rose 14.26% to $16.5. The company's market cap stands at $17.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Koninklijke Philips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) stock decreased by 16.9% to $26.31 during Monday's pre-market session. The market value of their outstanding shares is at $24.5 billion. The company's, Q3 earnings came out today. </li>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) stock decreased by 12.88% to $14.75. The company's market cap stands at $51.9 million. </li>
<li>Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) shares declined by 10.84% to $0.36. The market value of their outstanding shares is at $19.8 million. </li>
<li>Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) stock declined by 8.29% to $1.55. The company's market cap stands at $110.5 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) shares decreased by 7.94% to $0.37. The company's market cap stands at $26.4 million. </li>
<li>Mobile-health Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) shares decreased by 7.92% to $0.44. The company's market cap stands at $14.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACRS

AVTX

MNDR

MRNS

PRCT

RVNC

XAIR

12 Health Care Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock increased by 93.4% to $1.12 during Monday's pre-market session. The market value of their outstanding shares is at $6.3 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares rose 71.53% to $9.09. The market value of their outstanding shares is at $6.6 million. </li>
<li>Monte Rosa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLUE#NASDAQ">GLUE</a>) shares moved upwards by 32.1% to $6.46. The market value of their outstanding shares is at $396.4 million. </li>
<li>Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) shares moved upwards by 22.27% to $1.18. The company's market cap stands at $18.9 million. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) stock rose 21.04% to $5.69. The company's market cap stands at $592.6 million. </li>
<li>Mira Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) stock moved upwards by 15.5% to $1.49. The market value of their outstanding shares is at $22.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Koninklijke Philips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) stock declined by 17.0% to $26.29 during Monday's pre-market session. The market value of their outstanding shares is at $24.5 billion. As per the news, the Q3 earnings report came out today. </li>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) stock fell 12.88% to $14.75. The company's market cap stands at $51.9 million. </li>
<li>Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) stock decreased by 10.84% to $0.36. The market value of their outstanding shares is at $19.8 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock declined by 9.84% to $0.32. The company's market cap stands at $4.7 million. </li>
<li>Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) shares declined by 8.88% to $1.54. The market value of their outstanding shares is at $109.8 million. </li>
<li>Mobile-health Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) stock decreased by 8.06% to $0.44. The market value of their outstanding shares is at $14.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ENSC

MIRA

Biotech

General

Evoke Pharma Announces Presentation Of Data For GLP-1 Users With Diabetic Gastroparesis Using GIMOTI Showing Statistically Significant Improvement For GIMOTI Over Oral Metoclopramide In All Cause Emergency Department Visits, All Cause Office Visits And All Cause Hospital Outpatient Visits

Nantahala to nominate 2 board seats
Portion of the proceeds received from warrants executed at $8.16/share
SOLANA BEACH, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>), a specialty pharmaceutical company focused on developing treatments for gastrointestinal (GI) diseases, with a particular emphasis on GIMOTI&#xAE; (metoclopramide) nasal spray, announced today that it received approximately $3.0 million in gross proceeds from the amendment and exercise of existing warrants.
The approximately $3.0 million in gross proceeds will be used to support working capital and general corporate purposes, including advancing the commercial efforts for GIMOTI. Details of the exercised warrants can be found in the corresponding SEC filing. No new warrants were issued with these transactions which closed on September 30, 2024.

Evoke Pharma Announces It Recieved $3M In Gross Proceeds From Existing Warrants And Board Expansion; Portion Of The Proceeds Received From Warrants Executed At $8.16/share

<a href="https://www.globenewswire.com/Tracker?data=kXC5zwQobnwJ5tuHPOAJ6PRRMWtoTywyxfs_zeap6YEYFsLA5wSyuoSjT52Uy9zuGU9Ty-L3lVzkhL5ffGzpYbCcDhWpxxnFV7goFgHCYRQ=">Evoke Pharma, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti&#xAE;&nbsp;(metoclopramide) nasal spray, reaffirms its commitment to improving the lives of patients suffering from diabetic gastroparesis in light of the recent decision by the U.S. Food and Drug Administration (FDA) to not approve Vanda Pharmaceuticals new drug application (NDA) for Tradipitant, an oral drug candidate for the treatment of symptoms in gastroparesis. Patients suffering from all forms of gastroparesis need additional agents to help treat this difficult disease, and we believe patients will be disappointed given the FDA's decision. Evoke continues to serve as a trusted partner for healthcare professionals and patients alike with its proven product, Gimoti&#xAE; (metoclopramide), the first and only FDA-approved nasal spray treatment for acute and recurrent diabetic gastroparesis in adults.

VNDA

Evoke Pharma Reaffirms Its Commitment To Improving The Lives Of Patients Suffering From Diabetic Gastroparesis In Light Of The Recent Decision By The U.S. FDA To Not Approve Vanda Pharmaceuticals NDA For Tradipitant, An Oral Drug Candidate For The Treatment Of Symptoms In Gastroparesis

Evoke Pharma Shares Halted To The Downside; Stock Now Down -7.90%

Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) reported quarterly losses of $(0.93) per share which missed the analyst consensus estimate of $(0.06) by 1450 percent. This is a 66.07 percent decrease over losses of $(0.56) per share from the same period last year. The company reported quarterly sales of $2.55 million which missed the analyst consensus estimate of $2.98 million by 14.38 percent. This is a 125.58 percent increase over sales of $1.13 million the same period last year.

Evoke Pharma Q2 EPS $(0.93) Misses $(0.06) Estimate, Sales $2.55M Miss $2.98M Estimate

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Evoke Pharma Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares ended Tuesday down 16.40% to 42 cents after the company announced a <a href="https://www.benzinga.com/pressreleases/24/07/g40036131/evoke-pharma-inc-announces-reverse-stock-split">1-for-12 reverse stock split</a> of its common stock, set to take effect at 12:01 a.m. ET on August 1, 2024. After-hours trading has it up 12.44% at 47 cents.
The reverse stock split means that every 12 shares of the company&#8217;s existing common stock will be consolidated into one share. The stock will trade on a split-adjusted basis on NASDAQ under the same symbol, EVOK, starting Aug. 1.
This reverse split, approved by shareholders at the 2024 annual meeting, will not change the par value or the authorized number of shares. Fractional shares will not be issued; instead, shareholders will receive a cash payment for any fractional shares.
Read Also: <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/07/40048366/post-it-manufacturer-3m-sticks-landing-while-ford-tanks-biggest-beats-and-misses-fro">Post-it Manufacturer 3M Sticks Landing While Ford Tanks: Biggest Beats And Misses From Earnings Season So Far</a>
<h2 class="wp-block-heading">Should I Buy, Hold or Sell My EVOK Stock?</h2>
When deciding to buy, hold or sell a stock, investors should consider their time horizon, unrealized gains and total return.
Shares of Evoke Pharma have decreased by 75.13% in the past year. An investor who bought shares of Evoke Pharma at the beginning of the year would take a loss of $0.64 per share if they sold it today. The stock has fallen 16.7% over the past month, meaning an investor who bought shares on Jun. 1 would see a capital loss of $0.11.
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Evoke Pharma stock currently has an RSI of 28.29, indicating oversold conditions.
For access to advanced charting and analysis tools and stock data, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a>
EVOK has a 52-week high of $1.67 and a 52-week low of 36 cents.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/07/40044042/job-openings-hold-steady-in-june-ahead-of-crucial-july-labor-market-data-why-this" target="_blank" rel="noreferrer noopener">Job Openings Hold Steady In June Ahead Of Crucial July Labor Market Data: Why This Analyst Expects Robust Payrolls</a></li>
</ul>

Stock Split

Why Evoke Pharma (EVOK) Stock Is Volatile

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Evoke Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/evok-stock-quote/">EVOK</a>) just reported results for the second quarter of 2024.<ul><li>Evoke Pharma reported earnings per share of -93 cents. This was below the analyst estimate for EPS of -6 cents.</li><li>The company reported revenue of $2.55 million.</li><li>This was 14.40% worse than the analyst estimate for revenue of $2.98 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/evok-stock-earnings-evoke-pharma-for-q2-of-2024/">EVOK Stock Earnings: Evoke Pharma Misses EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

EVOK Stock Earnings: Evoke Pharma Misses EPS, Misses Revenue for Q2 2024

Evoke Pharma files for mixed shelf offering

Evoke Pharma files for $50M mixed securities shelf

Evoke Pharma announces proceeds from existing warrants and board expansion

Evoke Pharma (EVOK) announced the appointment of Ben Smeal to serve on the Company's Board of Directors effective October 18, 2024. This appointmen...

Evoke Pharma appoints Ben Smeal to board of directors

Evoke Pharma ( ($EVOK) ) just unveiled an announcement. Evoke Pharma, Inc. has appointed Benjamin Smeal as a Class II director with a term expiring...

Evoke Pharma Appoints Benjamin Smeal as Director

Evoke stock rockets 90% on study of Gimoti in GLP-1 users

09:35 EDT Evoke Pharma (EVOK) trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-moving...

Evoke Pharma trading halted, volatility trading pause

Evoke Pharma GAAP EPS of -$0.94, revenue of $2.65M

Evoke Pharma Inc ( ($EVOK) ) has released its Q3 earnings. Here is a breakdown of the information Evoke Pharma Inc presented to its investors. Evok...

Evoke Pharma Reports Q3 2024 Financial Results

Press Releases

Evoke Pharma, Inc. Supports Gastroparesis Awareness Month

Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results

Evoke Pharma to Present at H.C. Wainwright's 26th Annual Global Investment Conference

Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference

Health Care

Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments

Financing

Management

Evoke Pharma Announces Proceeds from Existing Warrants and Board Expansion

Evoke Pharma Announces the Appointment of Ben Smeal to the Board of Directors

Evoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific Meeting

Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI®

Comments

Evoke Pharma

Notizie

Ultime notizie per Evoke Pharma (NASDAQ:EVOK) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO